You are here: Industry Insights > Eisai

News List

CFDA accepts Eisai's NDA for cancer drug biospectrumasia
November 01, 2017
Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017).
Eisai banks on potential of Biogen’s Alzheimer’s drug pharmafile
October 25, 2017
Drug developers investigating Alzheimer’s drugs know that they’re taking a gamble; there have been numerous big failures that have caused larger companies to shy away from the difficult-to-treat area.
Eisai announces combined clinical trial results on cancer biospectrumasia
September 14, 2017
Appropriate monitoring of Quality-Of-Light and continuous treatment via anticancer agents allow for maximum patient benefit.
Real-world data prove efficacy of Eisai and Bial's epilepsy treatment pharmafile
September 07, 2017
Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset epilepsy in adults
Eisai seeks marketing authorisation for lenvatinib from EMA pharmaceutical-technology
July 31, 2017
Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).
Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia pharmaceutical-technology
April 06, 2017
Japanese companies Eisai and Meiji Seika Pharma have signed an agreement for the commercialisation of safinamide to treat Parkinson’s disease in Japan and Asia.
Clinigen and Eisai partner to offer Halaven for metastatic breast cancer in South Africa pharmaceutical-technology
March 01, 2017
Japanese pharmaceutical company Eisai has partnered with UK-based pharmaceutical and services firm Clinigen Group to distribute Halaven (eribulin) in South Africa for the treatment of women with metastatic breast cancer.
Eisai acquires manufacturing rights for API from Roche to treat insomnia pharmaceutical-technology
January 19, 2017
Eisai has acquired the rights for manufacturing active pharmaceutical ingredients (API) for Japan from F Hoffman-La Roche for the insomnia treatment / anaesthesia induction agent flunitrazepam.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page